Akoya Biosciences names former molecular diagnostics CEO as new board chair
Image | Courtesy of Google Maps
Akoya Biosciences' Marlborough headquarters
Marlborough-based biotech firm Akoya Biosciences has named Scott Mendel, the former president and CEO of a California-based molecular diagnostics firm, as its new chair of its board of directors.
Mendel has been named the chair of the board effective immediately, according to an Akoya press release on Thursday, replacing founding chairperson Robert Shepler, who has retained a seat on the board.
“I am thrilled to continue working with Akoya’s management team to capitalize on the Company’s leadership position in Spatial Biology,” Mendel said in the press release. “I intend to leverage my public company experience to assist in delivering on Akoya’s potential and maximizing shareholder return.”
Mendel served as the president and CEO of GenMark Diagnostics, a publicly-traded molecular diagnostics company from May 2020 until April 2021, when the company was acquired by Switzerland-based Roche for $1.8 billion. Prior to GenMark, Mendel served as the CFO of The Active Network, a global cloud-based software company based in Dallas. Mendel also serves as a board member for Visby Medical, a California-based medical technology manufacturer, according to his LinkedIn profile.
Founded in 2015, Akoya became a publicly traded company on the Nasdaq in 2021 following an initial public offering, which raised $151 million. The company opened an additional facility in Marlborough in May to help meet demand for its spatial biology imaging equipment.
On Friday morning, the company’s stock was trading at $2.58 per share.
Eric Casey is a staff writer at Worcester Business Journal, who primarily covers the manufacturing and real estate industries.
WBJ Web Partners
Most Recent
Most Recent
0 Comments